RANBAXY

Ranbaxy Laboratories Limited has informed the Exchange regarding Press Release dated February 2, 2015, titled "Sun Pharma receives US FTC clearance for Ranbaxy acquisition".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated January 28, 2015 titled "Ranbaxy Q3 FY 2015 Sales Rs.25,876 Mn. YTD Dec'14 Sales Rs.81,778 Mn".

Ranbaxy Laboratories Limited has informed the Exchange regarding Press Release dated December 15, 2014 titled "RANBAXY COMMENCES LAUNCH OF INDIA'S FIRST NCE, SYNRIAM IN AFRICAN COUNTRIES".

Ranbaxy Laboratories Limited has informed the Exchange regarding a joint Press Release dated December 8, 2014 titled "CCI approves Ranbaxy acquisition by Sun Pharma".

Ranbaxy Laboratories Limited has informed the Exchange regarding Press Release dated December 1, 2014, titled "Ranbaxy launches India's first biosimilar of Infliximab drug, InfimabTM".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated November 5, 2014 titled "Ranbaxy Receives Approval from US FDA to Market Fenofibrate Capsules USP, 43mg and 130mg".

Ranbaxy Laboratories Limited has informed the Exchange regarding Press Release dated October 28, 2014, titled "Ranbaxy Q2FY 2015 Sales Rs.32,180Mn. H1 FY2015 Sales Rs.55,902 Mn".

Ranbaxy Laboratories Limited has informed the Exchange regarding press release dated October 1, 2014 titled "Ranbaxy Launches ABSORICA (isotretinoin) 25 mg and 35 mg Capsules in the U.S. Market".

Ranbaxy Laboratories Limited has informed the Exchange with reference to the Press Release dated July 29, 2014 titled "Ranbaxy Q1 FY 2015 (Apr 14-Jun 14) Sales Rs.23.7 Bn - Growth registered in Base business profitability" issued by the Company. The Company has now informed that the said press release, under the head Key Financial Highlights , inadvertently there was a typo error. The corresponding period for Consolidated sales should be read as Apr-Jun 2013 instead of Jan-Mar 2014 . Accordingly, the revised statement would be as under: Consolidated Sales were Rs.23.7 Bn [Apr-Jun 2013: Sales

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated July 29, 2014 titled "Ranbaxy Q1 FY 2015 (Apr'14-Jun'14) Sales Rs.23.7 Bn Growth registered in Base business profitability".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated July 24, 2014, titled "Ranbaxy and Cipher Announce Signing of Licensing Agreement for Isotretinoin".

Ranbaxy Laboratories Limited has informed the Exchange vide letter dated June 27, 2014 regarding a press release dated June 26, 2014, titled"OHM LABORATORIES TO LAUNCH VALSARTAN TABLETS".

Ranbaxy Laboratories Limited has submitted to the Exchange a copy of Press Release dated May 9, 2014 titled "Ranbaxy January- March2014 Sales at Rs.24.4Bn - Achieved sales guidance with Rs.130.4Bn for the 15 months period ended March 2014 -Growth registered in Base business sales and EBITDA"

Ranbaxy Laboratories Limited has informed the Exchange regarding the press release dated April 07, 2014 titled, "Sun Pharma to acquire Ranbaxy in a US$ 4 Billion Landmark transaction."

Ranbaxy Laboratories Limited has informed the Exchange regarding the press release dated February 5, 2014 titled,"Ranbaxy Q4 FY14 Sales Rs.28.6 Bn. YTD Dec 2013 Sales Rs.106.0 Bn - Base business grows by 10%+ QoQ and on YTD basis - Robust growth in EBITDA during the quarter and on YTD"

Ranbaxy Laboratories Limited has submitted to the Exchange a copy of press statement dated January 24, 2014 which is being issued by the Company.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated January 09, 2014, titled "Ranbaxy and EPIRUS Announces Signing of Licensing Agreement for Biosimilar Product; Ranbaxy to market in India and other Emerging Markets, after approval".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated January 08, 2014, titled "RANBAXY RECEIVES APPROVAL TO MARKET RAN - DONEPEZIL IN CANADA".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated November 20, 2013 titled "RANBAXY COMPLETES 20 YEARS IN UKRAINE".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated October 29, 2013 titled "Ranbaxy Q3 CY 2013 Sales Rs.27.5 Bn. YTD Sep 2013 Sales Rs.77.5 Bn".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated October 21, 2013 titled "Ranbaxy receives CDSCO approval to market Synriam(TM) in India for treatment of malaria caused by Plasmodium vivax parasite".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated September 19, 2013, titled"Ranbaxy Receives Paragraph IV Certication".

Ranbaxy Laboratories Limited has informed the Exchange regarding press release dated September 05, 2013 titled "Ranbaxy Completes 20 Years in Russia".

Ranbaxy Laboratories Limited has informed the Exchange regarding the press release dated August 8, 2013 titled,"Ranbaxy allocated site for its Greenfield manufacturing facility in Malaysia-Agreement signed with Kulim Hi Tech Park."

Ranbaxy Laboratories Limited has informed the Exchange regarding Press Release dated August 7, 2013 titled "Ranbaxy Q2 CY 2013 Sales Rs.26,332 Mn. H1 CY2013 Sales Rs.50,730 Mn -Base business sales and margins grow"

Ranbaxy Laboratories Limited has submitted to the Exchange a copy of Press Statement dated May 31, 2013, which is being issued by the Company on May 31, 2013.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated May 22, 2013, titled" Ranbaxy Highlights Improved Business and Quality Assurance Standards".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated May 13, 2013, titled" Ranbaxy announces conclusion of previously disclosed investigation by U.S. Department Of Justice".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated May 08, 2013, titled "Ranbaxy Q1 CY 2013 Sales Rs.24,398 Mn. Base business grows by over 10%".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated April 17, 2013 titled "Daiichi Sankyo and Ranbaxy launch hybrid business in Brazil to expand business of both companies".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated April 17, 2013, titled "Daiichi Sankyo and Ranbaxy launch hybrid business in Brazil to expand business of both companies".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated April 01, 2013, titled "Ranbaxy resumes the supply of Atorvastatin tablets to the US market".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated March 05, 2013, titled "Ranbaxy to market Desvenlafaxine Base Extended Release Tablets in The US".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated February 26, 2013, titled "Ranbaxy surpass 2012 guidance; Crosses Rs.120 Bn in Global sales".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated January 16, 2013, titled "Daiichi Sankyo and Ranbaxy to leverage synergies in Thailand".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated November 26, 2012, titled "Ranbaxy Launches Absorica (Isotretinoin) Capsules in the U.S. Healthcare Market".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated November 08, 2012, titled "Ranbaxy delivers strong overall business performance; Improvement in base business sales and margins".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated October 09, 2012, titled "RANBAXY LAUNCHES AUTHORIZED GENERIC OF EVOXAC IN THE U.S. HEALTHCARE MARKET".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated September 13, 2012, titled "RANBAXY GETS APPROVAL TO SET UP GREENFIELD MANUFACTURING FACILITY IN MALAYSIA".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated August 17, 2012, titled "Ranbaxy launches authorized Generic of Pioglitazone in the U.S.".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated August 09, 2012, titled "Ranbaxy returns sales growth of 55% in Q2 2012 with stronger profitability; receives approval for multiple value added, differentiated products".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated August 03, 2012 titled "RANBAXY ENTERS INTO AN IN-LICENSING AGREEMENT WITH GILEAD SCIENCES TO PROMOTE ACCESS TO REDUCED COST GENERIC EMTRICITABINE AND EMTRICITABINE-CONTAINING FIXED-DOSE ANTIRETROVIRALS IN DEVELOPING COUNTRIES".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated June 20, 2012 titled "Daiichi Sankyo and Ranbaxy Launch Hybrid Business in Venezuela".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated May 28, 2012, titled "Ranbaxy Announces USFDA Approval of CIP-ISOTRETINOIN NDA".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated May 09, 2012, titled "Ranbaxy sales grew over 55% with improvement in base business profitability".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated April 25, 2012, titled "RANBAXY LAUNCHES SYNRIAM - INDIA'S FIRST NEW DRUG".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated April 19, 2012, titled "Daiichi Sankyo and Ranbaxy to expand Hybrid Business Model in Romania".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated April 13, 2012, titled "Ranbaxy adjudged Malaysian Pharmaceutical Company of the Year for 2012".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated April 02, 2012, titled "Ranbaxy's Mohali SEZ Facility begins export of Atorvastatin to the US market".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated March 31, 2012, titled "RANBAXY RECEIVES APPROVAL TO MARKET RAN(TM) ROSUVASTATIN IN CANADA".